We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Glaukos Corp
1 own
7 watching
Current Price
$51.52
$-0.96
(-1.83%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
2,455.7M
52-Week High
64.49
52-Week Low
33.33
Average Volume
0.42M
Dividend Yield
--
P/E Ratio
--
Market Capitalization2,455.7M52-Week High64.4952-Week Low33.33Average Volume0.42MDividend Yield--P/E Ratio--What does the Glaukos Corp do?
Glaukos Corporation, an ophthalmic medical technology company, focuses on the development and commercialization of products and procedures designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry with the goal of achieving intraocular pressure reduction; iStent Supra suprachoroidal micro-bypass stent, which is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. It markets its products through direct sales force in the United States and internationally, as well as through distribution partners in Europe, the Asia Pacific, and internationally. Glaukos Corporation was founded in 1998 and is headquartered in San Clemente, California.
Read More
How much money does Glaukos Corp make?
News & Events about Glaukos Corp.
Ticker Report
1month ago
Glaukos (NYSE:GKOS Get Rating) was upgraded by stock analysts at StockNews.com from a sell rating to a hold rating in a research report issued to clients and investors on Friday. A number of other analysts also recently issued reports on the stock. Citigroup ...
Zolmax
1month ago
Glaukos (NYSE:GKOS Get Rating) was upgraded by equities researchers at StockNews.com from a sell rating to a hold rating in a note issued to investors on Friday. GKOS has been the subject of several other research reports. Mizuho assumed coverage on shares of Glaukos in a research note on Thursday. ...
Ticker Report
1month ago
Shares of Glaukos Co. (NYSE:GKOS Get Rating) have been assigned an average recommendation of Hold from the ten analysts that are currently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and ...
Zolmax
2 months ago
Shares of Glaukos Co. (NYSE:GKOS Get Rating) have been assigned a consensus recommendation of Hold from the ten brokerages that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and ...
Zolmax
5 months ago
Swiss National Bank increased its position in Glaukos Co. (NYSE:GKOS Get Rating) by 8.4% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 110,800 shares of the medical instruments suppliers stock after acquiring an ...
Frequently Asked Questions
Frequently Asked Questions
What is Glaukos Corp share price today?
Can Indians buy Glaukos Corp shares?
How can I buy Glaukos Corp shares from India?
Can Fractional shares of Glaukos Corp be purchased?
What are the documents required to start investing in Glaukos Corp stocks?
What is today’s traded volume of Glaukos Corp?
What is today’s market capitalisation of Glaukos Corp?
What is the 52-Week High and Low Range of Glaukos Corp?
What percentage is Glaukos Corp down from its 52-Week High?
What percentage is Glaukos Corp up from its 52-Week Low?
Current Price
$51.52
$-0.96
(-1.83%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.